Elsevier

The Lancet

Volume 331, Issue 8598, 11 June 1988, Pages 1295-1298
The Lancet

PHASE I CLINICAL TRIAL OF A WORLD HEALTH ORGANISATION BIRTH CONTROL VACCINE

https://doi.org/10.1016/S0140-6736(88)92117-4Get rights and content

Abstract

A birth control vaccine incorporating a synthetic peptide antigen representing the aminoacid sequence 109-145 of the C-terminal region of the β subunit of human chorionic gonadotropin (hCG-β) was submitted to a phase 1 clinical trial. Thirty surgically sterilised female volunteers, divided into five equal groups for different vaccine doses, received two intramuscular injections six weeks apart. Over a six-month follow-up there were no important adverse reactions, and potentially contraceptive levels of antibodies to hCG developed in all subjects. In the highest vaccine dose group, the results gave promise of a contraceptive effect of six months' duration.

References (16)

There are more references available in the full text version of this article.

Cited by (0)

View full text